Skip to main content
Shuo Ma, MD, Oncology, Chicago, IL, Northwestern Memorial Hospital

ShuoMaMDPhD

Oncology • Chicago, IL

Hematologic Oncology

Associate Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine

Join to view full profile

Dr. Ma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ma's full profile

Already have an account?

Summary

  • Dr. Shuo Ma is an oncologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. She received her medical degree from Beijing Medical University and has been in practice 23 years. She specializes in hematologic oncology and is experienced in chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM) and non-Hodgkin lymphomas.

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Ascension Illinois/Saint Joseph (Chicago)
    Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 2002 - 2005
  • Brigham and Women's Hospital
    Brigham and Women's HospitalPost-Doctoral Fellowship, Vascular Biology, 2000 - 2002
  • Northwestern University
    Northwestern UniversityPhD, Cell and Molecular Biology, 1994 - 2000
  • Beijing Medical University
    Beijing Medical UniversityClass of 1994

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2002 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
    Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
    Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Press Mentions

  • Modern COVID-19 Vaccine May Be More Effective for Cancer Patients
    Modern COVID-19 Vaccine May Be More Effective for Cancer PatientsApril 29th, 2022
  • Moderna’s COVID-19 Vaccine May Be More Effective for Cancer Patients
    Moderna’s COVID-19 Vaccine May Be More Effective for Cancer PatientsApril 29th, 2022
  • CLL: Undetectable Disease Likely with Ibrutinib plus Venetoclax
    CLL: Undetectable Disease Likely with Ibrutinib plus VenetoclaxDecember 14th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Shuo Ma, Dr. Shuo Ma, MD, Dr. S Ma